Targeting HIF-1α downstream pathways: The suppression of tumor growth and improvement in treatment outcomes can be achieved by inhibiting HIF-1α-regulated genes involved in angiogenesis (e.g., vascular endothelial growth factor (VEGF) inhibitors) or glycolysis (e.g., glycolytic enzyme inhibitors) [32]. Here, VEGFA is linked to neoplasm.